Reuters logo
10 months ago
BRIEF-Celyad says NKR-2 phase I safety trial delivers encouraging results
November 7, 2016 / 6:17 AM / 10 months ago

BRIEF-Celyad says NKR-2 phase I safety trial delivers encouraging results

Nov 7 (Reuters) - Celyad SA :

* NKR-2 phase I safety trial delivers encouraging results to be presented at ASH 2016

* In trial were no cases of cytokine release syndrome, cell-related neurotoxicity, auto-immunity, or CAR-T related death

* Re-assured to note that the safety outcome of this phase I study confirms the pre-clinical animal data generated to date Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below